HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $50 price target on the company's stock.
January 02, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating and a $50 price target for Biora Therapeutics, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can lead to increased investor confidence and a potential short-term uplift in Biora Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100